TP53 and cancer: In the present study, we successfully established a cytarabine-resistant cell line, called MV4-11-R, from the parental cell line MV4-11-P and characterized its growth properties, phosphorylation of kinases, FLT3-ITD mutation status and signaling, TP53 expression and mutations, cytarabine metabolic enzymes and transporters, and responses to anti-cancer drugs (especially cabozantinib) both in vitro and in vivo.